Eli Lilly and Company (NYSE:LLY) Position Decreased by Kimelman & Baird LLC
Kimelman & Baird LLC cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.9% during the first quarter, Holdings Channel reports. The fund owned 159,583 shares of the company’s stock after selling 1,380 shares during the period. Eli Lilly and comprises 2.0% of Kimelman & Baird LLC’s holdings, making the stock its 16th largest position. Kimelman & Baird LLC’s holdings in Eli Lilly and were worth $13,423,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after buying an additional 59,978,664 shares during the last quarter. Beutel Goodman & Co Ltd. acquired a new stake in Eli Lilly and during the first quarter valued at $161,084,000. Vanguard Group Inc. boosted its stake in Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after buying an additional 2,181,701 shares during the last quarter. Winslow Capital Management LLC boosted its stake in Eli Lilly and by 79.7% in the first quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock valued at $326,008,000 after buying an additional 1,719,538 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Eli Lilly and by 93.6% in the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock valued at $250,681,000 after buying an additional 1,441,200 shares during the last quarter. 75.59% of the stock is currently owned by hedge funds and other institutional investors.
Eli Lilly and Company (NYSE LLY) traded up 0.425% during trading on Monday, reaching $81.495. The company had a trading volume of 507,698 shares. The company has a market capitalization of $85.98 billion, a PE ratio of 35.264 and a beta of 0.34. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72. The firm’s 50 day moving average is $82.91 and its 200 day moving average is $81.72.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the business posted $0.86 EPS. On average, equities research analysts predict that Eli Lilly and Company will post $4.16 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be paid a $0.52 dividend. The ex-dividend date is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a yield of 2.56%. Eli Lilly and’s dividend payout ratio (DPR) is 90.04%.
TRADEMARK VIOLATION WARNING: This news story was published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/eli-lilly-and-company-nyselly-position-decreased-by-kimelman-baird-llc/1487149.html.
LLY has been the topic of several recent analyst reports. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $92.00 price target on shares of Eli Lilly and in a report on Tuesday, May 16th. BMO Capital Markets set a $71.00 price target on Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, April 25th. Zacks Investment Research cut Eli Lilly and from a “buy” rating to a “hold” rating in a report on Tuesday, April 18th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $87.00 price target on shares of Eli Lilly and in a report on Wednesday, April 19th. Finally, Argus cut Eli Lilly and from a “buy” rating to a “hold” rating and raised their price objective for the company from $64.18 to $81.00 in a report on Thursday, April 27th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $88.27.
In other Eli Lilly and news, VP Michael J. Harrington sold 22,833 shares of Eli Lilly and stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the completion of the transaction, the vice president now owns 62,056 shares in the company, valued at approximately $4,962,618.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of Eli Lilly and stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $83.09, for a total value of $18,279,800.00. Following the transaction, the insider now owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The disclosure for this sale can be found here. Insiders sold a total of 669,733 shares of company stock valued at $55,845,287 in the last 90 days. 0.20% of the stock is currently owned by company insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.